Prevalence of unexplained erythrocytosis and thrombocytosis–an NHANES analysis

Douglas Tremblay; Naomi Alpert; Emanuela Taioli; John Mascarenhas

doi:10.1080/10428194.2021.1888377

Prevalence of unexplained erythrocytosis and thrombocytosis–an NHANES analysis

Douglas Tremblay, Naomi Alpert, Emanuela Taioli, John Mascarenhas

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	2030-2033
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	62
Issue number	8
DOIs	https://doi.org/10.1080/10428194.2021.1888377
State	Published - 2021

Access to Document

10.1080/10428194.2021.1888377

Cite this

@article{3fd66242ce7e484582e098a9a32e0198,

title = "Prevalence of unexplained erythrocytosis and thrombocytosis–an NHANES analysis",

author = "Douglas Tremblay and Naomi Alpert and Emanuela Taioli and John Mascarenhas",

note = "Funding Information: Dr. Mascarenhas reports grants and personal fees from Incyte, grants from CTI Biopharma, grants from Janssen, grants and personal fees from Roche, grants and personal fees from Promedior, personal fees from Celgene-BMS, grants and personal fees from Kartos, grants from Novartis, grants from Merus, grants from Arog, grants from Forbius, personal fees from Geron, personal fees from Constellation, personal fees from Prelude, outside the submitted work. The rest of the coauthors have no conflicts of interest to disclose.",

year = "2021",

doi = "10.1080/10428194.2021.1888377",

language = "English",

volume = "62",

pages = "2030--2033",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Prevalence of unexplained erythrocytosis and thrombocytosis–an NHANES analysis

AU - Tremblay, Douglas

AU - Alpert, Naomi

AU - Taioli, Emanuela

AU - Mascarenhas, John

N1 - Funding Information: Dr. Mascarenhas reports grants and personal fees from Incyte, grants from CTI Biopharma, grants from Janssen, grants and personal fees from Roche, grants and personal fees from Promedior, personal fees from Celgene-BMS, grants and personal fees from Kartos, grants from Novartis, grants from Merus, grants from Arog, grants from Forbius, personal fees from Geron, personal fees from Constellation, personal fees from Prelude, outside the submitted work. The rest of the coauthors have no conflicts of interest to disclose.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85101803037&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.1888377

DO - 10.1080/10428194.2021.1888377

M3 - Letter

C2 - 33645402

AN - SCOPUS:85101803037

SN - 1042-8194

VL - 62

SP - 2030

EP - 2033

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 8

ER -